Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ICC International Cannabis Corp WLDCF

ICC International Cannabis Corp is a Canadian company which is engaged in planning, designing, building and operating cannabis production, processing, and distribution facilities worldwide. The company through its holdings is engaged in the pharmaceutical distribution, wholesale importation, research, and development, as well as working interests in industrial hemp licenses in Greece, licenses to cultivate, produce, distribute, store, and export Cannabis and Cannabis derivatives in Colombia, the


OTCPK:WLDCF - Post by User

Post by graciouson Apr 05, 2018 8:18am
194 Views
Post# 27834357

news

newsFrom TD


ICC Labs Announces New Initiative to Conduct Various Scientific and Medicinal Research Activities

5 minutes ago by GlobeNewswire
Companies Mentioned: ICCLF
 

ICC Labs Inc. ("ICC Labs" or the "Company") (TSX-V:ICC) (Frankfurt:2Q9) is pleased to announce that it and one of its Uruguayan subsidiaries have entered into a framework collaboration agreement (the "Framework Agreement") with the Pasteur Institute of Montevideo, a Uruguayan foundation devoted to biomedical research.

In accordance with the Framework Agreement, ICC Labs will provide the Pasteur Institute with various cannabinoid extracts and the Pasteur Institute will conduct scientific and medicinal research programs (the "Research Programs"). Each Research Program will be subject to regulatory approval and to further definitive agreements that will define the specific contributions of the parties. Under the Framework Agreement, the Research Program will be managed by a steering committee consisting of two representatives of ICC Labs and two representatives of the Pasteur Institute. It is the intent of the parties that the results of the Research Program, whether patentable or not, will be owned solely by ICC Labs. Any inventions that occur incidental to the Research Program will be subject to a co-ownership agreement between the parties.

In addition to the above, ICC Labs is pleased to announce its first Research Program with the Pasteur Institute. Over a period of two years, ICC Labs will provide US$400,000 in funding and three phytocannabinoid extracts to the Research Program and the Pasteur Institute will conduct various scientific and medicinal research activities designed to ascertain potential effects of the phytocannabinoids on immune response, neuroprotection and intestinal microbiota.

Alejandro Antalich, the CEO of ICC Labs, commented: "We are very committed to this framework for the development of pharmaceutical products, and the related impact on the scientific community. With this first step we are seeking to innovate in the use of new medicines applied to different clinical pathologies, and to generate and making available to the global health community the necessary tools for proper medical prescriptions related to cannabinoids. We are excited by the search for new solutions for a better quality of life, and to reduce the suffering caused by different diseases and the side effects of the treatments used to combat them."

<< Previous
Bullboard Posts
Next >>